Ignite Creation Date:
2024-05-05 @ 4:43 PM
Last Modification Date:
2024-10-26 @ 9:22 AM
Study NCT ID:
NCT00290849
Status:
COMPLETED
Last Update Posted:
2012-05-07
First Post:
2005-12-14
Brief Title:
ImproveR International BI-001-IM
Sponsor:
Nycomed
Organization:
Nycomed
Study Overview
Official Title:
European Registry of Consecutive Patients Undergoing PCI Evaluating the Use of the Thrombin-specific Anticoagulant Bivalirudin With Focus on Patient Selection Convenience and Safety Aspects
Status:
COMPLETED
Status Verified Date:
2010-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The objectives of this registry are to assess the use of the thrombin-specific anticoagulant bivalirudin during percutaneous coronary intervention PCI in a real life setting In particular data will be collected to analyze experiences of bivalirudin use in respect to the following objectives
examine the aspects of safety and effectiveness of bivalirudin
gain experience regarding the characteristics of patients in bivalirudin treatment
evaluate the handling of bivalirudin and its practicality
examine the aspects of safety and effectiveness of bivalirudin
gain experience regarding the characteristics of patients in bivalirudin treatment
evaluate the handling of bivalirudin and its practicality
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None